{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T13:00:29Z","timestamp":1781614829563,"version":"3.54.5"},"reference-count":35,"publisher":"Georg Thieme Verlag KG","issue":"CP","license":[{"start":{"date-parts":[[2025,1,10]],"date-time":"2025-01-10T00:00:00Z","timestamp":1736467200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["TH Open"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Cancer-associated thrombosis affects between 1 and 20% of all patients diagnosed with cancer and is associated with significant morbidity and a poorer prognosis. Risk assessment scores exist which include the measurement of biomarkers, and which aim to identify patients at a higher risk of developing thrombotic events, but these are poor predictors and rarely used in routine clinical practice.<\/jats:p><jats:p>VEGF is a potent angiogenic factor, produced by tumour cells, and released by platelets and is essential for tumour growth and progression. It also plays a role in the promotion of thrombosis through platelet activation and adhesion, and by inducing the expression of tissue factor. Therefore, the potential of VEGF to be used as a biomarker to predict cancer-associated thrombosis requires further investigation.<\/jats:p><jats:p>This study reviewed the published literature to determine whether circulating VEGF levels are associated with increased risk of venous thromboembolism in patients with cancer.<\/jats:p><jats:p>PubMed and OVID databases were systematically searched according to PRISMA guidelines for relevant papers using the keywords \u201ccancer\u201d AND \u201cthrombosis\u201d AND \u201cVEGF\u201d up to July 2023. Inclusion and exclusion criteria were applied.<\/jats:p><jats:p>Seven papers (1,528 participants) were identified and included in the meta-analysis, three of which (922 participants) measured VEGF before a thrombotic event, and the remaining four (606 participants) measured VEGF at the time of the thrombosis. Our results showed that although plasma and serum VEGF tended to be higher in those who subsequently developed thrombosis than those who did not (mean difference 70.2 pg\/mL for serum, and 11.44 pg\/mL for plasma VEGF, 95% CI \u22122.39\u201325.73, p\u2009=\u20090.10), this was not found to be statistically significant. However, analysis of VEGF following blood sampling at the time of thrombosis showed a stronger statistically significant association between increased VEGF levels and presence of thrombosis (mean difference 117.02 pg\/mL for serum, and 116.6 pg\/mL for plasma VEGF, 95% CI 55.42\u2013190.82, p\u2009=\u20090.0004).<\/jats:p><jats:p>Based on current studies, whilst it is increased at the time of thrombosis, VEGF is not effective as a predictive biomarker of CAT.<\/jats:p>","DOI":"10.1055\/a-2513-4381","type":"journal-article","created":{"date-parts":[[2025,1,11]],"date-time":"2025-01-11T00:15:59Z","timestamp":1736554559000},"source":"Crossref","is-referenced-by-count":3,"special_numbering":"S","title":["Vascular Endothelial Growth Factor (VEGF) as a Biomarker for Cancer-Associated Venous Thrombosis: A Meta-analysis"],"prefix":"10.1055","volume":"09","author":[{"given":"Alison M.","family":"Brown","sequence":"additional","affiliation":[{"name":"Department of Blood Sciences, The Newcastle upon Tyne Hospitals NHS Foundation Trust, United Kingdom"},{"name":"Department of Life Sciences, Faculty of Science and Engineering, Manchester Metropolitan University, Manchester, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Nock","sequence":"additional","affiliation":[{"name":"Department of Life Sciences, Faculty of Science and Engineering, Manchester Metropolitan University, Manchester, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn","family":"Musgrave","sequence":"additional","affiliation":[{"name":"Haematology Department, The Newcastle upon Tyne Hospitals NHS Foundation Trust, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3809-5984","authenticated-orcid":false,"given":"Amanda J.","family":"Unsworth","sequence":"additional","affiliation":[{"name":"Thrombosis Collective, Leeds Institute of Cardiovascular and Metabolic Medicine, Faculty of Medicine and Health, University of Leeds, Leeds, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2025,2,10]]},"reference":[{"issue":"01","key":"ref1","doi-asserted-by":"crossref","first-page":"28","DOI":"10.3816\/SCT.2005.n.022","article-title":"Venous thromboembolism in patients with cancer and its relationship to the coagulation cascade and vascular endothelial growth factor","volume":"3","author":"M Dogan","year":"2005","journal-title":"Support Cancer Ther"},{"issue":"04","key":"ref2","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1001\/archinte.166.4.458","article-title":"Incidence of venous thromboembolism and its effect on survival among patients with common cancers","volume":"166","author":"H K Chew","year":"2006","journal-title":"Arch Intern Med"},{"issue":"09","key":"ref3","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.3324\/haematol.2017.169060","article-title":"Comparison of risk prediction scores for venous thromboembolism in cancer patients: a prospective cohort study","volume":"102","author":"N van Es","year":"2017","journal-title":"Haematologica"},{"issue":"04","key":"ref4","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1182\/bloodadvances.2020003442","article-title":"American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer","volume":"5","author":"G H Lyman","year":"2021","journal-title":"Blood Adv"},{"issue":"05","key":"ref5","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1111\/bjh.13556","article-title":"Guideline on aspects of cancer-related venous thrombosis","volume":"170","author":"H G Watson","year":"2015","journal-title":"Br J Haematol"},{"issue":"10","key":"ref6","doi-asserted-by":"crossref","first-page":"4902","DOI":"10.1182\/blood-2007-10-116327","article-title":"Development and validation of a predictive model for chemotherapy-associated thrombosis","volume":"111","author":"A A Khorana","year":"2008","journal-title":"Blood"},{"issue":"24","key":"ref7","doi-asserted-by":"crossref","first-page":"5377","DOI":"10.1182\/blood-2010-02-270116","article-title":"Prediction of venous thromboembolism in cancer patients","volume":"116","author":"C Ay","year":"2010","journal-title":"Blood"},{"issue":"S 01","key":"ref8","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/S0049-3848(20)30389-3","article-title":"Risk prediction for cancer-associated thrombosis in ambulatory patients with cancer: past, present and future","volume":"191","author":"F Moik","year":"2020","journal-title":"Thromb Res"},{"issue":"19","key":"ref9","doi-asserted-by":"crossref","first-page":"2878","DOI":"10.3748\/wjg.v10.i19.2878","article-title":"Expression of plasma vascular endothelial growth factor in patients with hepatocellular carcinoma and effect of transcatheter arterial chemoembolization therapy on plasma vascular endothelial growth factor level","volume":"10","author":"X Li","year":"2004","journal-title":"World J Gastroenterol"},{"issue":"04","key":"ref10","first-page":"206","article-title":"The effect of venous thromboembolism on survival of cancer patients and its relationship with serum levels of factor VIII and vascular endothelial growth factor: a prospective matched-paired study","volume":"21","author":"M Dogan","year":"2006","journal-title":"Int J Biol Markers"},{"issue":"01","key":"ref11","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1158\/1078-0432.CCR-14-3358","article-title":"Soluble vascular endothelial growth factor (sVEGF) and the risk of venous thromboembolism in patients with cancer: result from the Vienna cancer and thrombosis study","volume":"22","author":"F Posch","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"03","key":"ref12","first-page":"487","article-title":"Leukocytes and platelets of patients with cancer contain high levels of vascular endothelial growth factor","volume":"5","author":"P Salven","year":"1999","journal-title":"Clin Cancer Res"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"3929435","DOI":"10.1155\/2020\/3929435","article-title":"The abnormal expression of miR-205-5p, miR-195-5p, and VEGF-A in human cervical cancer is related to the treatment of venous thromboembolism","volume":"2020","author":"Y Wang","year":"2020","journal-title":"BioMed Res Int"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.jclinepi.2021.02.003","article-title":"Updating guidance for reporting systematic reviews: development of the PRISMA 2020 statement","volume":"134","author":"M J Page","year":"2021","journal-title":"J Clin Epidemiol"},{"issue":"07","key":"ref15","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1038\/sj.bjc.6604620","article-title":"Early changes in the haemostatic and procoagulant systems after chemotherapy for breast cancer","volume":"99","author":"C C Kirwan","year":"2008","journal-title":"Br J Cancer"},{"issue":"01","key":"ref16","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/2040-2384-1-7","article-title":"Platelet release of vascular endothelial growth factor (VEGF) in patients undergoing chemotherapy for breast cancer","volume":"1","author":"C C Kirwan","year":"2009","journal-title":"J Angiogenes Res"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"e076754","DOI":"10.1136\/bmj-2023-076754","article-title":"ROB-ME: a tool for assessing risk of bias due to missing evidence in systematic reviews with meta-analysis","volume":"383","author":"M J Page","year":"2023","journal-title":"BMJ"},{"issue":"07","key":"ref19","first-page":"774","article-title":"Elevated serum vascular endothelial growth factor levels in patients with polycythemia vera and thrombotic complications","volume":"87","author":"R R Cacciola","year":"2002","journal-title":"Haematologica"},{"issue":"12","key":"ref20","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.3390\/cancers11122020","article-title":"Low systemic levels of chemokine C\u2013C motif ligand 2 (CCL3) are associated with a high risk of venous thromboembolism in patients with glioma","volume":"11","author":"P MS Nazari","year":"2019","journal-title":"Cancers (Basel)"},{"issue":"03","key":"ref21","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1002\/ajh.10020","article-title":"Soluble angiogenic factors: implications for chronic myeloproliferative disorders","volume":"69","author":"C Musolino","year":"2002","journal-title":"Am J Hematol"},{"issue":"04","key":"ref22","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1093\/jjco\/hyh039","article-title":"Serum vascular endothelial growth factor per platelet count in hepatocellular carcinoma: correlations with clinical parameters and survival","volume":"34","author":"S J Kim","year":"2004","journal-title":"Jpn J Clin Oncol"},{"issue":"08","key":"ref23","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1080\/07357907.2021.1951751","article-title":"Correlation between vascular endothelial growth factor and long-term occurrence of HCV-related hepatocellular carcinoma after treatment with direct-acting antivirals","volume":"39","author":"H K Ramadan","year":"2021","journal-title":"Cancer Invest"},{"issue":"07","key":"ref24","doi-asserted-by":"crossref","first-page":"e0132496","DOI":"10.1371\/journal.pone.0132496","article-title":"Increased levels of NF-kB-dependent markers in cancer-associated deep venous thrombosis","volume":"10","author":"G Malaponte","year":"2015","journal-title":"PLoS One"},{"issue":"10","key":"ref25","doi-asserted-by":"crossref","first-page":"2870","DOI":"10.1158\/1078-0432.CCR-06-2351","article-title":"Tissue factor expression, angiogenesis, and thrombosis in pancreatic cancer","volume":"13","author":"A A Khorana","year":"2007","journal-title":"Clin Cancer Res"},{"issue":"03","key":"ref26","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1172\/JCI117451","article-title":"Tissue factor controls the balance of angiogenic and antiangiogenic properties of tumor cells in mice","volume":"94","author":"Y Zhang","year":"1994","journal-title":"J Clin Invest"},{"issue":"01","key":"ref27","doi-asserted-by":"crossref","first-page":"267","DOI":"10.3390\/cancers3010267","article-title":"The hemostasis apparatus in pancreatic cancer and its importance beyond thrombosis","volume":"3","author":"H Echrish","year":"2011","journal-title":"Cancers (Basel)"},{"key":"ref28","first-page":"2187","article-title":"Platelet: transporter of vascular endothelial growth factor","volume":"3","author":"H M Verheul","year":"1997","journal-title":"Clin Cancer Res"},{"issue":"17","key":"ref29","doi-asserted-by":"crossref","first-page":"4663","DOI":"10.1182\/blood-2011-06-362392","article-title":"The utility of plasma vascular endothelial growth factor levels in the diagnosis and follow-up of patients with POEMS syndrome","volume":"118","author":"A D'Souza","year":"2011","journal-title":"Blood"},{"issue":"01","key":"ref30","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1002\/(SICI)1097-0142(19990101)85:1<178::AID-CNCR25>3.0.CO;2-7","article-title":"Vascular endothelial growth factor in the sera and effusions of patients with malignant and nonmalignant disease","volume":"85","author":"A Kraft","year":"1999","journal-title":"Cancer"},{"issue":"04","key":"ref31","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1111\/jth.12515","article-title":"D-dimer as a predictor of venous thromboembolism in acutely ill, hospitalized patients: a subanalysis of the randomized controlled MAGELLAN trial","volume":"12","author":"A T Cohen","year":"2014","journal-title":"J Thromb Haemost"},{"issue":"01","key":"ref32","doi-asserted-by":"crossref","first-page":"4836","DOI":"10.1038\/s41598-017-05210-6","article-title":"Serum D-dimer is a potential predictor for thromboembolism complications in patients with renal biopsy","volume":"7","author":"X Tan","year":"2017","journal-title":"Sci Rep"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.thromres.2021.10.020","article-title":"Elevated plasma D-dimer levels are associated with risk of future incident venous thromboembolism","volume":"208","author":"E-S Hansen","year":"2021","journal-title":"Thromb Res"},{"issue":"S 01","key":"ref34","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1111\/ijlh.12665","article-title":"Review of D-dimer testing: good, bad, and ugly","volume":"39","author":"L-A Linkins","year":"2017","journal-title":"Int J Lab Hematol"},{"issue":"03","key":"ref35","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/s11739-012-0784-y","article-title":"A modified Khorana risk assessment score for venous thromboembolism in cancer patients receiving chemotherapy: the Protecht score","volume":"7","author":"M Verso","year":"2012","journal-title":"Intern Emerg Med"},{"issue":"09","key":"ref36","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.1016\/j.jtha.2023.04.038","article-title":"Plasma levels of P-selectin and future risk of incident venous thromboembolism","volume":"21","author":"S Swamy","year":"2023","journal-title":"J Thromb Haemost"}],"container-title":["TH Open"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2513-4381.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,11]],"date-time":"2025-02-11T00:21:57Z","timestamp":1739233317000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2513-4381"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,10]]},"references-count":35,"journal-issue":{"issue":"CP","published-online":{"date-parts":[[2025,1,27]]},"published-print":{"date-parts":[[2025]]}},"alternative-id":["a25134381"],"URL":"https:\/\/doi.org\/10.1055\/a-2513-4381","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["2512-9465"],"issn-type":[{"value":"2512-9465","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,1,10]]},"published":{"date-parts":[[2025,1,10]]}}}